Acute Systemic Complications Following High-Dose Semaglutide Reinitiation in an Elderly Patient

Area of Science:

• Endocrinology
• Pharmacology
• Gastroenterology

Background:

• Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely used for type 2 diabetes and obesity.
• Patients may interrupt semaglutide treatment for various reasons, leading to treatment holidays.
• Resuming therapy after an interruption requires careful consideration of potential adverse events.

Purpose of the Study:

• To highlight the risk of severe gastrointestinal intolerance and systemic complications upon reinitiating high-dose semaglutide after a treatment interruption.
• To identify patient populations, such as the elderly with comorbidities, who may be more vulnerable to these adverse effects.
• To provide clinical guidance on safely restarting semaglutide therapy.

Main Methods:

• This is a clinical observation and recommendation based on patient outcomes.
• Analysis of adverse event reports following semaglutide treatment resumption.
• Review of patient profiles, including age, comorbidities, and prior tolerance.

Main Results:

• Severe gastrointestinal intolerance and systemic complications can manifest rapidly (within hours) after restarting high-dose semaglutide.
• These adverse effects can occur even in patients who previously tolerated the medication well.
• Elderly patients with existing comorbidities appear to be at higher risk.

Conclusions:

• Clinicians must be aware of the potential for severe adverse events when reintroducing semaglutide after a prolonged interruption.
• Re-titration from lower doses is recommended when restarting GLP-1 receptor agonists following drug holidays.
• This approach aims to mitigate the risk of severe gastrointestinal intolerance and associated complications, enhancing patient safety.